Rapid diagnostic testing for influenza, offered through distributors like McKesson, provides clinicians with timely information to guide patient care. These tests detect viral antigens or genetic material from a patient sample, typically a nasal or throat swab. Results are usually available within 15-30 minutes, enabling prompt treatment decisions and potentially reducing unnecessary antibiotic prescriptions.
Access to efficient and accurate influenza diagnostics contributes to better patient outcomes, particularly for vulnerable populations. Rapid identification helps manage outbreaks in healthcare settings and communities by facilitating timely isolation and infection control measures. The historical development of these tests, from early culture-based methods to sophisticated molecular assays, reflects advancements in diagnostic technology and ongoing efforts to improve disease surveillance.
